The FreeStyle Libre by Abbott can provide prick-free on-demand sugar readings that offer detailed insights with just a scan ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Worldwide Medical Devices sales increased 11.7% on a reported basis and 13.3% on an organic basis in the third quarter, ...

With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets.

DexCom markets one of the world's most popular constant blood glucose monitors (CGM). These discreet devices adhere to the ...

In recent years, its FreeStyle Libre franchise of continuous glucose ... while its adjusted earnings per share rose by 10.2% to $2.82. Though headwinds might affect its results in the short ...

Abbott Libre (Libre 2 and Libre 3) Very similar to G6/G7 but ... 1s show better blood sugar levels when also utilising their Freestyle Libre 3. Abbott and DexCom have pushed this message ...

The FreeStyle Libre is only responsible for about 15% of ... obesity or overweight reduced their risk of progression to type 2 diabetes by 94% with weekly tirzepatide injections.

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...